regenerative partnerships Position Organicell as a partner for contract development and manufacturing of exosome-based biologics and perinatal-derived therapies, leveraging their Zofin platform and autologous Patient Pure X service to explore joint development, clinical trial supply, and regulatory support opportunities.

COPD and airway focus Target respiratory health stakeholders by highlighting ongoing IND activity for Zofin in COPD to pursue co-development, investigator-initiated trials, and companion diagnostic or biomarker studies that align with chronic lung disease programs.

exosome booster potential Explore collaborations with consumer wellness and dermatology players interested in exosome-based skin aging and inflammation boosters, building pilots around Hydrafacial and BeautyHealth-style applications to expand into cosmeceutical channels.

clinical-stage leveraging Offer clinical-stage partnerships to accelerate late-stage validation, with a focus on global partnering for regulatory filings, late-phase trials, and potential regional commercialization in biotech hubs given the company’s small-to-mid enterprise profile.

funding and services Propose services around regulatory strategy, IND/CTA enablement, and trial services tied to Organicell’s autologous PPX platform and perinatal-derived products to diversify revenue streams and attract biotech sponsors seeking specialized regenerative medicine capabilities.